CN110638902A - Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof - Google Patents

Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof Download PDF

Info

Publication number
CN110638902A
CN110638902A CN201910942950.9A CN201910942950A CN110638902A CN 110638902 A CN110638902 A CN 110638902A CN 201910942950 A CN201910942950 A CN 201910942950A CN 110638902 A CN110638902 A CN 110638902A
Authority
CN
China
Prior art keywords
tomato
extract
blood pressure
ethyl acetate
petroleum ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201910942950.9A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bai Dongping
Original Assignee
Bai Dongping
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bai Dongping filed Critical Bai Dongping
Priority to CN201910942950.9A priority Critical patent/CN110638902A/en
Publication of CN110638902A publication Critical patent/CN110638902A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a blood pressure reducing composition, which comprises the following components in parts by weight: 40-50 parts of tomato extract and 12-20 parts of Arabic gum, wherein the tomato extract is a combination of tomato petroleum ether extract and tomato ethyl acetate extract, and the weight ratio of the tomato petroleum ether extract to the tomato ethyl acetate extract is as follows: the mass ratio of the tomato ethyl acetate extract is (10-40): (12-35). The research of the invention shows that the blood pressure reducing composition has good blood pressure reducing effect by controlling the weight ratio of the tomato extract to the Arabic gum, particularly, the blood pressure reducing effect is remarkably improved under the limited ratio of the invention, and a new choice is provided for clinical medication.

Description

Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof
Technical Field
The invention relates to the technical field of blood pressure reduction, and particularly relates to application of a tomato extract in preparation of a blood pressure reducing medicine and a blood pressure reducing composition thereof.
Background
Hypertension is the most common chronic disease and the most main risk factor of cardiovascular and cerebrovascular diseases, and stroke, myocardial infarction, heart failure and chronic kidney disease are main complications of the hypertension. The practice at home and abroad proves that the hypertension is a disease which can be prevented and controlled, the blood pressure level of a hypertension patient is reduced, the stroke and the heart disease events can be obviously reduced, the life quality of the patient is obviously improved, and the disease burden is effectively reduced. The risk of hypertension is related to the blood pressure level of the patient and depends on the risk factors of other cardiovascular diseases, target organ damage and other diseases combined. Therefore, in the definition and classification of hypertension, the diagnostic criteria of hypertension are defined as systolic pressure ≥ 140mmHg and/or diastolic pressure ≥ 90mmHg, and are classified according to blood pressure level into normal, normal high-value blood pressure and 1, 2, 3-stage blood pressure, and at the same time, risk stratification is performed according to risk factors, target organ damage and other diseases which are simultaneously complicated. The prevalence of hypertension increases with age; the prevalence rate of women is slightly lower than that of men before menopause, but rises rapidly after menopause, even higher than that of men; the prevalence rate of the high-latitude cold area is higher than that of the low-latitude warm area, and the prevalence rate of the high-altitude area is higher than that of the low-altitude area; in connection with dietary habits, the higher the intake of salt and saturated fat, the higher the average blood pressure level and the prevalence. The hypertension prevalence of the population in China has two remarkable characteristics: from south to north, hypertension prevalence presents an increasing trend; the prevalence rate of hypertension is different among different nationalities, the prevalence rate of the nationalities living in northern areas or plateau areas is high, the prevalence rate of the nationalities living in southern areas or non-plateau areas is low, the difference can be related to geographical environments, life styles and the like, and obvious genetic background difference among the nationalities is not found. The main goal of treating hypertension is to minimize the overall risk of cardiovascular morbidity and mortality, thus requiring physicians to intervene in all reversible cardiovascular risk factors, target organ damage and the clinical complications present in patients while treating hypertension. The blood pressure reduction target is below 140/90mmHg for general hypertensive patients, and the blood pressure is reduced to a lower level as appropriate under the condition that the patients can tolerate the high-risk patients with combined diabetes or nephropathy.
In mature tomatoes, there is a large amount of a red-developing pigment, often referred to as lycopene. In the past, lycopene red has been used only as a natural pigment, and the pharmacological action thereof has been studied intensively. In recent years, more and more researchers have found that lycopene actually has many physiological activities and is a main carotenoid existing in human serum and other tissues. Known researches show that the lycopene is an excellent antioxidant, the antioxidant activity of the lycopene is obviously superior to that of other carotenoids, and the lycopene has obvious effects on regulating lipid metabolism, enhancing the immunity of the organism and the like. Lycopene, as a natural, safe and non-side-effect food, has attracted extensive attention for its physiological functions, and especially its activity in anti-tumor aspect, has become a hot spot of present research.
Lycopene is a fat-soluble pigment, insoluble in water, insoluble in strongly polar solvents such as methanol and ethanol, and soluble in organic solvents such as aliphatic hydrocarbons, aromatic hydrocarbons and chlorinated hydrocarbons such as ethane, benzene and chloroform. The solubility of lycopene in various solvents increases with increasing temperature.
Disclosure of Invention
The invention provides an application of tomatoes in preparing a blood pressure reducing medicine and a blood pressure reducing composition thereof, and aims to provide a new application of a tomato extract.
The invention provides a blood pressure reducing composition which comprises the following components in parts by weight: 40-50 parts of tomato extract and 12-20 parts of Arabic gum, wherein the tomato extract is a combination of tomato petroleum ether extract and tomato ethyl acetate extract, and the weight ratio of the tomato petroleum ether extract to the tomato ethyl acetate extract is as follows: the mass ratio of the tomato ethyl acetate extract is (10-40): (12-35).
As a further improvement of the invention, the tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is 10:12 or 40:35 or 10:35 or 12: 40.
The invention further protects the application of the blood pressure reducing composition in preparing a blood pressure reducing medicine.
As a further improvement of the invention, the pharmaceutical preparation is an oral preparation, an injection preparation or a transdermal absorption preparation.
The invention further protects the application of the blood pressure reducing composition in preparing blood pressure reducing health-care food, food and special medical diet.
The invention further provides a blood pressure lowering granule which is prepared from the following raw materials: the tomato flavoring agent comprises tomato extract, Arabic gum, a mixture of dextrin and starch, a wetting agent, a flavoring agent and a binder, wherein the flavoring agent is stevioside, the binder is water, and the wetting agent is a 70% ethanol solution.
As a further development of the invention, the tomato extract is a combination of tomato petroleum ether extract and tomato ethyl acetate extract, wherein the ratio of tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is (10-40): (12-35).
The invention further provides a preparation method of the blood pressure lowering particles, which comprises the following steps:
s1, preparing an artichoke extract: cleaning and drying tomatoes, soaking in petroleum ether, heating to 35-40 deg.C with microwave, extracting for 30min, filtering, collecting filtrate, removing solvent under reduced pressure to obtain tomato petroleum ether extract, adding ethyl acetate into the residue, stirring and extracting for 1h, filtering, and rotary steaming under reduced pressure to remove solvent to obtain tomato ethyl acetate extract;
s2, dry powder preparation: mixing the tomato petroleum ether extract and the tomato ethyl acetate extract uniformly according to the proportion, grinding and sieving;
s3, preparing particles: weighing the mixture of dry powder, dextrin and starch, mixing well, adding correctant, spraying wetting agent and adhesive, making into soft material, granulating with screen, drying at 60-75 deg.C under normal pressure for 1 hr, and grading with 20 mesh sieve to obtain granule for lowering blood pressure.
As a further development of the invention, the wetting agent: adhesive: flavoring agent: mixture of dextrin and starch: the mass ratio of the dry powder is 1 (2-5): (0.5-1): (35-70):50, and the mass ratio of the dextrin to the starch in the mixture of the dextrin and the starch is 1: 2.
As a further improvement of the invention, the mesh number of the screen in the step S2 is 100 meshes, and the mesh number of the screen granulation in the step S3 is 12 meshes.
The invention has the following beneficial effects: the research of the invention shows that the blood pressure reducing composition has good blood pressure reducing effect by controlling the weight ratio of the tomato extract to the Arabic gum, particularly, the blood pressure reducing effect is remarkably improved under the limited ratio of the invention, and a new choice is provided for clinical medication.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Preparing a tomato extract:
s1, preparing a tomato petroleum ether extract:
cleaning fructus Lycopersici Esculenti, drying to water content less than 5%, chopping 100g of dried fructus Lycopersici Esculenti, soaking in petroleum ether at solid-to-liquid ratio of 1:50g/mL, heating to 35-40 deg.C with 1000w microwave, extracting for 30min, filtering, collecting filtrate, and removing solvent under reduced pressure to obtain 157mg of petroleum ether extract of fructus Lycopersici Esculenti;
s2, preparing a tomato ethyl acetate extract:
adding ethyl acetate into the residue at a solid-to-liquid ratio of 1:30g/mL, stirring at 500r/min for 1 hr, filtering, and rotary steaming under reduced pressure to remove the solvent to obtain tomato ethyl acetate extract 59 mg.
Example 2
Preparing the blood pressure lowering particles:
s1, dry powder preparation: according to the tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is 10:12, the tomato petroleum ether extract and the tomato ethyl acetate extract are uniformly mixed, and are ground and sieved by a 100-mesh sieve;
s2, preparing particles: weighing 50g of dry powder and 35g of a mixture of dextrin and starch (the mass ratio of the dextrin to the starch is 1:2), fully and uniformly mixing, adding 0.5g of stevioside, sequentially spraying 1g of 70% ethanol solution and 2g of water, preparing into a soft material, granulating by using a 12-mesh screen, drying for 1h at 60 ℃ under normal pressure, and grading by using a 20-mesh screen to prepare the blood pressure reducing granules.
Example 3
Preparing the blood pressure lowering particles:
s1, dry powder preparation: according to the tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is 40:35, the tomato petroleum ether extract and the tomato ethyl acetate extract are uniformly mixed, and are ground and sieved by a 100-mesh sieve;
s2, preparing particles: weighing 50g of dry powder and 70g of a mixture of dextrin and starch (the mass ratio of the dextrin to the starch is 1:2), fully and uniformly mixing, adding 1g of stevioside, sequentially spraying 1g of 70% ethanol solution and 5g of water, preparing into a soft material, granulating by using a 12-mesh screen, drying for 1h at 75 ℃ under normal pressure, and grading by using a 20-mesh screen to obtain the blood pressure reducing granules.
Test example 1 Rabbit experiment
1.1 materials and reagents
The tomato petroleum ether extract and the tomato ethyl acetate extract are provided by the embodiment 1 of the invention, and the tomatoes are provided by the vegetable research center of the agricultural academy in Hunan province; acacia gum, supplied by zhengzhou guebets food additives limited; nifedipine, provided by Liaoning benign (group) Defeng pharmaceutical Co., Ltd, was prepared into 2.0mg/mL with physiological saline, and other reagents were all domestic analytical purifications.
1.2 Experimental instruments
BL-420E biosignal acquisition processing system (Gentle science Inc.), pressure transducer.
1.3 Experimental animals
120 healthy adult rabbits with the weight of 2-2.5 kg and unlimited sexes are provided by southern medical university animal center (Guangdong medical practice Standard No. 07).
2. Experimental methods
2.1 animal grouping and modeling: 120 rabbits were randomly divided into 12 groups, i.e., high, medium, and low doses of tomato extract, model group, positive control group, normal group, petroleum ether extract group of tomato, ethyl acetate extract group of tomato, gum arabic group, composition 1 group, composition 2 group, and composition 3 group, which were 12 groups, each group consisting of 10 rabbits. Except for the normal control group, the rabbits were subjected to a double renal artery stenosis improvement, and the left and right renal artery trunks were ligated together with silver clips, resulting in renal artery insufficiency and renal hypertension model. After feeding for 4 weeks, experiments were performed.
2.2, anesthesia: rabbits were weighed and anesthetized by periaural intravenous injection of 1% sodium pentobarbital (30 mg/kg).
2.3, operation: fixing the anesthetized rabbit on a rabbit dissecting table, cutting a 3-7cm skin incision in the middle of the neck, separating a section of common carotid artery, tying the distal end with a line, tying a virtual knot at the proximal end with a line for standby, clamping the proximal end with an artery clamp, cutting a small opening close to the common carotid artery, inserting an arterial tube filled with heparin normal saline into the common carotid artery, immediately tying and fixing, inputting the blood pressure change into a biological signal acquisition and processing system through a pressure transducer for recording and processing, and applying a preload of about 160 mmHg.
2.4 administration
And (5) releasing the artery clamp, measuring the blood pressure, and recording the blood pressure before administration after the blood pressure of the rabbits is stable. Model rats were recovered for 1 week after surgery, then gavage was started for 30 days and the life status of the rats was monitored.
Normal group (normal saline, dosage 2.5g/kg), model group (normal saline, dosage 2.5g/kg), positive control group (nifedipine, dosage 0.015g/kg), high, medium and low dosage groups of tomato extract (dosage 5.0g/kg, 2.5g/kg and 1.75g/kg respectively), petroleum ether extract group of tomato (dosage 2.5g/kg), ethyl acetate extract group of tomato (dosage 2.5g/kg), acacia gum group (dosage 2.5g/kg), composition 1 group (dosage 2.5g/kg), composition 2 group (dosage 2.5g/kg) and composition 3 group (dosage 2.5g/kg), the model control group and the normal control group are injected with normal saline, and the change of blood pressure and recovery time are observed.
2.5 Observation index
Mean arterial pressure (diastolic +1/3 pulse differential), percent blood pressure drop, and heart rate.
2.6 statistical treatment
Data to
Figure RE-GDA0002262154940000081
The data analysis process is shown using SPSS 19.0 analysis software. Each time set up 3 parallel experiments. Significance testing was performed by one-way anova, comparison between groups by anova, p<A difference of 0.05 is significant.
3 results of the experiment
TABLE 1 Effect of tomato extract on blood pressure and Heart Rate in Kidney-type hypertensive rabbits: (
Figure RE-GDA0002262154940000082
n＝20)
Figure RE-GDA0002262154940000083
Figure RE-GDA0002262154940000091
Note: *: p <0.05, x: p <0.01, compared to normal group, #: p <0.05, # #: p <0.01 was compared to the model group.
The blood pressure comparison between the model group and the normal group is less than 0.01, and the comparison between the positive control group, the tomato extract high, medium and low dose group, the composition 1 group, the composition 2 group and the composition 3 group and the model group and the normal group is less than 0.05.
According to the results, after the gastric lavage tomato extract is administered to the rabbits of the hypertension model, the blood pressure is immediately and remarkably reduced, the action intensity is dose-dependent, the blood pressure of the rabbits in the high-dose group is reduced by 78%, the blood pressure reducing effect of the tomato extract in the medium dose is equivalent to that of nifedipine serving as a positive control drug, the effect of the high-dose group is better, and further observation shows that the blood pressure of the medium-dose group and the high-dose group is not increased after 2 hours after administration, the blood pressure of the low-dose group is increased after 60 minutes after administration, and the blood pressure is not recovered to the level before administration after 2 hours; the blood pressure of the composition 1 group, the composition 2 group and the composition 3 group is also remarkably reduced, wherein the blood pressure reducing effect of the composition 3 group is most obvious. However, it is shown that the blood pressure lowering effect of the tomato extract group and the tomato extract composition group is better than that of the single tomato petroleum ether extract, the tomato ethyl acetate extract or the acacia gum.
Composition 3 is obtained by compounding tomato extract and Arabic gum, and has synergistic effect in blood pressure lowering effect. The high, medium and low dosage groups of the tomato extract are obtained by compounding the tomato petroleum ether extract and the tomato ethyl acetate extract, and the compounding effect of the two is enhanced, so that the composition is obviously better than that of the single use.
4 conclusion
The medicine prepared by compounding the tomato extract and the Arabic gum or compounding the tomato petroleum ether extract and the tomato ethyl acetate extract has good blood pressure lowering effect.
Compared with the prior art, the research of the invention shows that the blood pressure reducing composition has good blood pressure reducing effect by controlling the weight ratio of the tomato extract to the Arabic gum, particularly, the blood pressure reducing effect is remarkably improved under the limited ratio of the invention, and a new choice is provided for clinical medication.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (10)

1. The composition for reducing blood pressure is characterized by comprising the following components in parts by weight: 40-50 parts of tomato extract and 12-20 parts of Arabic gum, wherein the tomato extract is a combination of tomato petroleum ether extract and tomato ethyl acetate extract, and the weight ratio of the tomato petroleum ether extract to the tomato ethyl acetate extract is as follows: the mass ratio of the tomato ethyl acetate extract is (10-40): (12-35).
2. The blood pressure lowering composition of claim 1, wherein the tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is 10:12 or 40:35 or 10:35 or 12: 40.
3. Use of the hypotensive composition according to claim 1 or 2 for the preparation of a hypotensive drug.
4. The use of claim 3, wherein the pharmaceutical formulation is an oral formulation, an injectable formulation or a transdermal formulation.
5. Use of the hypotensive composition according to claim 1 or 2 for the preparation of hypotensive health foods, foods and special medical diets.
6. The blood pressure reducing granule is characterized by being prepared from the following raw materials: the tomato flavoring agent comprises tomato extract, Arabic gum, a mixture of dextrin and starch, a wetting agent, a flavoring agent and a binder, wherein the flavoring agent is stevioside, the binder is water, and the wetting agent is a 70% ethanol solution.
7. The blood pressure lowering granule according to claim 6, wherein the tomato extract is a combination of tomato petroleum ether extract and tomato ethyl acetate extract, wherein the ratio of tomato petroleum ether extract: the mass ratio of the tomato ethyl acetate extract is (10-40): (12-35).
8. A method for preparing the blood pressure lowering particles according to claim 6 or 7, comprising the steps of:
s1, preparing an artichoke extract: cleaning and drying tomatoes, soaking in petroleum ether, heating to 35-40 deg.C with microwave, extracting for 30min, filtering, collecting filtrate, removing solvent under reduced pressure to obtain tomato petroleum ether extract, adding ethyl acetate into the residue, stirring and extracting for 1h, filtering, and rotary steaming under reduced pressure to remove solvent to obtain tomato ethyl acetate extract;
s2, dry powder preparation: mixing the tomato petroleum ether extract and the tomato ethyl acetate extract uniformly according to the proportion, grinding and sieving;
s3, preparing particles: weighing the mixture of dry powder, dextrin and starch, mixing well, adding correctant, spraying wetting agent and adhesive, making into soft material, granulating with screen, drying at 60-75 deg.C under normal pressure for 1 hr, and grading with 20 mesh sieve to obtain granule for lowering blood pressure.
9. The method of claim 8, wherein the wetting agent: adhesive: flavoring agent: mixture of dextrin and starch: the mass ratio of the dry powder is 1 (2-5): (0.5-1): (35-70):50, and the mass ratio of the dextrin to the starch in the mixture of the dextrin and the starch is 1: 2.
10. The method of claim 8, wherein the mesh size of the screen in step S2 is 100 meshes, and the mesh size of the screen in step S3 is 12 meshes.
CN201910942950.9A 2019-09-30 2019-09-30 Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof Withdrawn CN110638902A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910942950.9A CN110638902A (en) 2019-09-30 2019-09-30 Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910942950.9A CN110638902A (en) 2019-09-30 2019-09-30 Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof

Publications (1)

Publication Number Publication Date
CN110638902A true CN110638902A (en) 2020-01-03

Family

ID=69012062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910942950.9A Withdrawn CN110638902A (en) 2019-09-30 2019-09-30 Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof

Country Status (1)

Country Link
CN (1) CN110638902A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808626A (en) * 2007-07-12 2010-08-18 利库德有限公司 synergistic combinations for treating hypertension
CN104363774A (en) * 2012-04-23 2015-02-18 奥斯陆大学 Use of tomato extract as antihypertensive agent and process for making water soluble sugar free tomato extract
CN104688784A (en) * 2013-12-10 2015-06-10 成都百裕科技制药有限公司 Use of bilobalide in preparation of hypotensor
CN107106625A (en) * 2014-11-25 2017-08-29 利库德有限公司 The biological activity tomato compositions of lycopene with decrement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808626A (en) * 2007-07-12 2010-08-18 利库德有限公司 synergistic combinations for treating hypertension
CN104363774A (en) * 2012-04-23 2015-02-18 奥斯陆大学 Use of tomato extract as antihypertensive agent and process for making water soluble sugar free tomato extract
CN104688784A (en) * 2013-12-10 2015-06-10 成都百裕科技制药有限公司 Use of bilobalide in preparation of hypotensor
CN107106625A (en) * 2014-11-25 2017-08-29 利库德有限公司 The biological activity tomato compositions of lycopene with decrement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
YECHIEL N. ENGELHARD，等: "Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: A double-blind, placebo-controlled pilot study", 《AMERICAN HEART JOURNAL》 *
刘林林等: "从番茄渣中提取番茄红素的研究现状 ", 《中国果菜》 *
滕洁等: "番茄红素的提取及其微胶囊化 ", 《冷饮与速冻食品工业》 *
黄彤: "番茄红素的提取及抗氧化性", 《宜宾学院学报》 *

Similar Documents

Publication Publication Date Title
CN104739921B (en) A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue
CN109925310B (en) Hypotensive agent containing therapeutically effective amount of ginkgolides
CN106344648A (en) Thymus plant extract and application thereof
KR100949482B1 (en) Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof
CN102090637A (en) Collagen-containing compound nutritious powder
KR101359806B1 (en) Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same
CN110638902A (en) Application of tomato extract in preparation of antihypertensive drug and antihypertensive composition thereof
CN108434166B (en) Pharmaceutical composition for treating thromboembolism, preparation method, preparation and application thereof
CN101336965B (en) Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof
CN100581552C (en) Compound puerarin for treating cardiovascular and cerebrovascular disease
CN107136269B (en) Cyclocarya paliurus and bitter gourd blood sugar reducing tea and preparation method thereof
CN1997358A (en) The use of kauranes compounds in the preparation of medicament
KR101467407B1 (en) Antidiabetic food composition with the extract of Dendropanax morbifera
KR102234860B1 (en) Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract
CN105995971A (en) Nutritional liquid food for promoting diabetes recovery and preparation method thereof
JP2021159063A (en) Konjak functional food and method for producing the same
CN110638853A (en) Application of artichoke leaf extract in preparing medicine for lowering blood pressure and composition thereof
CN106344634B (en) A kind of mango bark extract and its preparation method and application
CN104688755B (en) The medical usage of Gardenoside
CN107998142B (en) A kind of combination of oral medication for treating myocardial ischemia-reperfusion injury
KR102527154B1 (en) Pharmaceutical composition for preventing or treating constipation with enhanced packaging stability comprising fermentation of Prunus domestica and Ficus carica as an active ingredient
CN106822157A (en) The therapeutic action of Ginsenoside compound K acute myocardial infarction
CN116920040B (en) Traditional Chinese medicine composition for treating acute myocardial infarction and preparation and application thereof
CN106822162A (en) The therapeutic action of ginseng sapoglycoside Rg 3 acute myocardial infarction
CN111803559B (en) Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20200103

WW01 Invention patent application withdrawn after publication